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Abstract
HIV-1 protease (HIV-PR) performs a vital step in the virus life cycle which makes it an excellent 
target for drug therapy. However, due to the error-prone of HIV reverse transcriptase, mutations in 
HIV-PR often occur, inducing drug-resistance to inhibitors. Some HIV-PR mutations can make the 
flaps of the enzyme more flexible thus increasing the flaps opening rate and inhibitor releasing. It 
has been shown that by targeting novel binding sites on HIV-PR with small molecules, it is 
possible to alter the equilibrium of flap conformational states. A previous fragment-based 
crystallographic screen have found two novel binding sites for small fragments in the inhibited, 
closed form of HIV-PR, termed flap and exo sites.
While these experiments were performed in wild type HIV-PR, it still remains to be proven 
whether these small fragments can stabilize the closed conformation of flaps in resistant forms of 
the enzyme.
Here we performed Molecular Dynamics simulations of wild type and mutant form of HIV-PR 
bound to inhibitor TL-3. Simulations show that on going from wild type to 6X mutant the 
equilibrium shifts from closed to semi-open conformation of flaps. However, when fragment Br6 
is placed at flap site of mutant form, the enzyme is restored back to closed conformation. This 
finding supports the hypothesis that allosteric inhibitors, together with active site inhibitors could 
increase the number of point mutations necessary for appreciable clinical resistance to AIDS 
therapy.
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HIV-1 protease (HIV-PR) performs a vital step in the life cycle of the Human 
immunodeficiency virus (HIV). HIV-PR break up gag / gag-pol polyproteins precursors into 
the mature protein components of an infectious virion. Drugs that are able to block HIV-PR 
function prevents virus maturation into its infective form.[1]
HIV-PR is a symmetrically assembled homo-dimer with the following structural segments: 
flap (residues 43–58/43’–58’), flap elbow (residues 35–42/35’−42’), fulcrum (residues 11–
22/11’–22’), cantilever (residues 59–75/59’–75’), dimerization interface (residues 1–
5/1’−5’, 95–99/95’−99’), active site (residues 23–30/23’–30’), 80s loop (76–84/76’−84’) 
and helix (86–90/86’−90’).
Ten protease inhibitors have been approved so far by the FDA, all of them bind to the active 
site of HIV-PR preventing virus maturation.[2] Nevertheless, because of the high error-prone 
of HIV-1 reverse transcriptase (HIV-RT) mutations in HIV-PR often arise during the course 
of treatment, inducing drug-resistance to above mentioned active site inhibitors.[3]
Experiments and theoretical studies revealed that HIV-PR can be in any of three 
conformations of the flaps: closed, semi-open, and fully open, which coexists in a dynamic 
equilibrium. In the apo state flaps are mostly open so that substrate can enter the active site. 
After substrate binding the flaps close around it to start the cleavage. The equilibrium among 
the functional conformations is controlled by the flexibility of flap regions. Mutations in 
HIV-PR can make the flaps more flexible and destabilize the closed conformation, thus 
increasing flaps opening rate and inhibitor releasing.[2]
Available structural models of HIV-PR mutant forms offers the possibility to understand the 
mechanisms by which the enzyme can overcome inhibition. Heaslet et al. have obtained the 
crystal structures of three mutant forms of HIV-PR containing one (1X: V82A), three (3X: 
V82A, M46I, F53L) and six (6X: V82A, M46I, F53L, V77I, L24I, L63P) point mutations. 
The three protease mutants arise sequentially during tissue culture in the presence of 
increasing concentrations of potent inhibitor TL-3 and exhibit 4, 11 and 30-fold resistance to 
TL-3, respectively.[4] The first mutation to arise in response to treatment with TL-3 was 
Val82 to Ala which is located in the 80s loop. This mutation perturbs hydrophobic 
interactions between flaps and 80s loop residues that help to maintain HIV-PR in the closed 
conformation.[2] After V82A mutation, two additional mutations, Met46 to Ile and Phe53 to 
Leu, both localized in the flap region of the protease further increased the mobility of the 
flaps. The third step in the evolution toward resistance resulted in the 6X protease mutant. 
The new mutations in the 6X protease are all distal to the protease flap regions, but still they 
are able to substantially affect the TL-3 binding site.[4]
Various strategies have been applied to develop new antiretroviral therapies against drug-
resistant forms of HIV-PR, from increasing the plasma levels of existing protease inhibitors 
by using a boosting agent to developing new protease inhibitors using structure-based drug 
design.[5] In a different approach Ung et al. has shown that by targeting novel binding sites 
on the surface of the HIV-PR with small molecules, it is possible to modulate the enzymatic 
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activity of the protease through altering the dynamics of the flaps and the equilibrium of the 
flap conformational states.[6]
In line with this novel approach some of us have performed a fragment-based 
crystallographic screen against inhibitor-bound HIV-PR to search for compounds that bind 
to novel sites and stabilize the inhibited conformation of the target.[7] The experiments have 
revealed two new binding sites for small fragments in the inhibited, closed form of the 
enzyme, termed flap site and exo sites; two of the 384 fragments screened bound in the flap 
site (1F1 and 1F1-N) and one in the exo site (4D9). Further work identified a third fragment 
hit that bound in the flap site and suggests that flap site binding favours a closed flap 
conformation of HIV-PR.[8] More recently, Tiefenbrunn et al. have screened a 68-member 
brominated fragment library against HIV-PR and led to the identification of two new 
compounds that also bind to the flap site (Br6) and exo site (Br27).[9] While these 
experiments were performed in wild type HIV-PR, it still remains to be proven whether 
these small fragments can stabilize the closed conformation of flaps in resistant forms of the 
enzyme.
In this work we have performed long Molecular Dynamics (MD) simulations of wild type 
(Wt) and 6X variant of HIV-PR bound to TL-3. The simulations show that when going from 
Wt to 6X the equilibrium shifts from closed to semi-open conformation of the flaps, in 
agreement with previous experimental and theoretical evidence. Then we placed small 
fragments Br6 and Br27 at flap site and exo site of 6X/TL-3 complex, respectively and 
performed MD simulations of the ternary complexes 6X/TL-3/Br6 and 6X/TL-3/Br27. To 
our surprise, one of the fragments, Br6, was able to restore back the enzyme to closed 
conformation of the flaps. That is to say, when Br6 is bound to one of the flaps of 6X it 
behaves much like the Wt form of HIV-PR. This finding supports the hypothesis already 
proposed by some of us [7] that allosteric inhibitors when administered together with active 
site inhibitors could likely increase the number of protease mutations necessary for 
appreciable clinical resistance to the highly active anti-retroviral therapy (HAART).
2 Computational Details
2.1 Simulation Protocol
Initial coordinates of Wt and 6X variant bound to TL-3 were obtained from the RCSB 
Protein Data Bank (codes 2AZ8 and 2AZC, respectively). Starting configurations of small 
fragments Br27 and Br6 in ternary complexes 6X/TL-3/Br27 and 6X/TL-3/Br6 respectively, 
were manually constructed based in the X-ray structures of Br27 bound to exo site (PDB 
code 4K4R) and Br6 bound to the flap site (PDB code 4K4Q).
All the simulations were carried out in triplicate (i.e. replicas 1, 2 and 3) with Amber14 
software package[10a] at 300°K temperature and extended up to 0.4 μs overall simulation 
time in a truncated octahedral periodic box of TIP3P water molecules. Amber ff14SB force 
field was used for proteins.[10b] The antechamber software in the AmberTools package was 
used to generate ligands (i.e. TL3, Br6 and Br27) parameters with GAFF force field and 
AM1-BCC charges.[10c] Every replica was run with the same random seed for velocity 
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profile generation, so that simulations within a replica are comparable among the different 
systems.
2.2 Dynamic Cross Correlation Analysis
Correlation between all proteins residues were analysed for the last 0.35 μs of each 
trajectory replica using the normalized covariance
Cij = Covi j/   (Δri t
2 ·  Δrj t
2)1/2 (1)
where Covij= <Δri(t) · Δrj(t)> and Δri(t)= ri(t) - <ri(t)>.
ri(t) is the position of node i at time t and < > represent time averaging. In this study, the 
correlation coefficients Cij have been computed by considering backbone carbon atoms of 
protein residues. Correlations were represented graphically with the help of Bio3D R 
package.[11]
2.3 Principal Components Analysis (PCA)
PCA calculations were performed with python package ProDy[12] on an ensemble of 
conformations derived from MD simulations to characterize collective protein motions. The 
resulting Principal Components (PCs) were sorted according to their contribution to the total 
fluctuation along the ensemble of conformations. It has been shown that only a small subset 
of these PCs describes a great majority of the total atomic displacement.[13] The calculation 
of the PCs involves two main steps: (1) the calculation of the covariance matrix, Covij, of the 
positional deviations, and (2) the diagonalization of this matrix which is equivalent to 
solving the eigenvalue problem.
2.4 Quantum Theory of Atoms in Molecules (QTAIM)
MD trajectories were projected along the first PC (PC1) and frames with extreme values of 
projection were selected for subsequent charge density topological analysis using QTAIM.
[14] This analysis has been very useful for evaluating the interactions in bio-molecular 
systems.[15–18]
Since accurate quantum calculations are still forbidden for full bio-molecular complexes, 
reduced 3D models were constructed from minimum and maximum extreme projection 
structures of complexes Wt/TL-3, 6X/TL-3 and 6X/TL-3/Br6. Fifty-two residues were 
included in the models: residues I13, K14, I15, G16, G17, Q18 and K20 from fulcrum; T31, 
V32, L33, E34, E35, M36, N37, L38, P39 and W42 from flap elbow; P44, K45, M46 (I46 in 
6X variant), I47, G48, G49, I50, G51, G52, F53 (L53 in 6X variant), I54, K55, V56, R57 
and Q58 from flap; Y59, I62, L63 (P63 in 6X variant), I64, E65 from cantilever; V75, L76, 
V77 (I77 in 6X variant), G78, P79, T80, P81, V82 (A82 for the 6X mutated variant), N83, 
I84 and I85 from 80’s loop. All these residues belong to monomer/chain A of the HIV-PR 
homo-dimmer while only four residues from monomer B flap tip were included in the 
reduced models: G49’, I50’, G51’ and G52’.
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Once the reduced models were constructed the charge density was computed by DFT 
methodology with the M06–2x dispersion corrected hybrid functional and 6–31G (d) as 
basis set, as implemented in Gaussian 09 package.[19] The topological analysis of charge 
density was then performed with the help of Multiwfn software.[20]
4 Results and Discussion
MD simulations of wild type and 6X mutant of HIV-PR were performed to investigate the 
effect of mutations on the dynamic of the flaps. Furthermore, simulations of 6X mutant 
bound to small fragments in the flap site and exo site were also carried out. In all system 
configurations the protease was bound to the same active site inhibitor TL-3.
4.1 Effect of mutations on the flexibility of the flaps
To inspect the motion of flaps along the MD trajectories, the distance I50-I50’ between 
residues from the tip of the flaps is depicted in Figure 1 for different system configurations.
Comparison of Wt/TL-3 and 6X/TL-3 complexes clearly shows that mutations in the 
protease turn flaps more prone for opening (see Figure 1). This finding is in agreement with 
previous studies that have shown that mutations in HIV-PR make the flaps more flexible and 
destabilize closed conformation.[2, 4]
To investigate the effect of non-active site binders on the flexibility of 6X mutant flaps, MD 
simulations of this protease variant with small fragment 1-bromo-2-naphthoic acid (Br27) 
bound to exo site and 3-bromo-2,6-dimethoxybenzoic acid (Br6) bound to flap site were 
performed.
Previous fragment-based crystallographic screens have reported that Br27 and Br6 bind to 
the exo site and flap site respectively and stabilize the closed conformation of the flaps in the 
wild-type HIV-PR.[9] However, to our knowledge the binding of these fragments to the 6X 
mutant has not been investigated yet. Moreover, flap flexibility is an inherently dynamic 
issue and thus, it cannot be entirely captured in a single crystal structure.
Analysis of the simulations reveals that Br27 is unable to maintain stable interactions with 
exo site residues and early detaches from this site during MD simulations. On the other hand 
Br6 remains bound to the flap site most of the time of the simulations, despite of the small 
size of Br6 and solvent exposure of flap site. Since only Br6 is able to maintain stable 
interactions within its native site as in the crystal structure, from now on the analysis is 
focused in this last fragment.
Figure 1 shows that when fragment Br6 is bound to flap site of 6X (i.e. system 6X/TL-3/
Br6) the flaps remain closed along the entire MD simulations. That is, the binding of Br6 to 
the flap suppress the tendency to flap opening in the 6X mutant. Moreover, the closing of the 
flaps in 6X/TL-3/Br6 is even more stable than in Wt/TL-3 itself, as evidenced in Figure 1.
In replica 2 of complex 6X/TL-3/Br6 the fragment detaches from the flap site during the 
simulations but it then re-attaches to another nearby site on the outside/top of the flap 
(Figure 2). Curiously, there seems to be no effect of the detachment of Br6 on the opening of 
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the flaps (Figure 1). This is probably because concerted motion of flap residues would take 
longer than the time period of Br6 detachment/re-attachment cycle.
In view of these findings, the following question arises: How residues from the flap tip 
where Br6 is bound communicate with residues from the other flap tip to trigger the closing 
of the flaps? Is this communication established directly from flap to flap or it might be 
mediated by intermediate residues from other sites of the protein? In other words we want to 
know how the binding of Br6 to the flap site compensates the effect of the mutations and 
suppress the flap opening tendency in 6X mutant.
To attempt answering these questions, in the next section we performed a dynamical cross 
correlation analysis (DCCA).
4.2 Dynamic Cross Correlation Analysis (DCCA)
DCCA is a technique extensively applied for analysing communications among separate 
parts of a molecular system and is usually employed to characterize the correlation in 
motion of protein residues along MD trajectories.[21] The correlation Cij between the 
residues falls in the range from −1 to 1. If the residues move in the same direction in most of 
the frames, the motion is considered to be correlated, and Cij will be positive. If they move 
in opposite directions in most frames, the motion is said to be anti-correlated, and Cij will be 
negative. If the correlation value between the 2 residues is close to zero, then the motion is 
said to be uncorrelated.[21]
Figure 3 shows the Dynamic Cross Correlation Maps (DCCMs) of complexes Wt/TL-3, 6X/
TL-3 and 6X/TL-3/Br6. Also 3D visualization of the positive correlations is shown for each 
system.
An overall negative correlation can be observed between both flaps in the three systems 
(black circled zones in the DCCMs). However, in Wt/TL-3 and 6X/TL-3/Br6 there is also a 
positive correlation zone between the tips of the flaps as indicated by an arrow in the 
DCCMs and by the red lines connecting both flap tips on the 3D protein structure. The 
positive correlation means that both flap tips move in the same direction and so they are 
maintained closed together most of the time of the simulations, thus preventing inhibitor 
releasing. On the other hand in system 6X/TL-3 the positive correlation between flap tips is 
not observed which is in line with the fact that flaps move apart from each other along the 
simulations.
Further information can be extracted from the correlation matrix by diagonalizing it (i.e. 
solving the eigenvalue problem) and analysing the first eigenvectors or Principal 
Components (PCs) which capture the essential dynamic of protein systems.[13]
4.3 Principal Component Analysis (PCA)
Figure 4 shows the first principal component (PC1) for systems Wt/TL-3, 6X/TL-3 and 6X/
TL-3/Br6. Since Br6 is bound to chain A of the homo-dimer (right chain of figure 4, 
residues 1 to 98) below we discussed the PC1 changes on this chain on going from Wt/TL-3 
to 6X/TL-3 to 6X/TL-3/Br6.
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In the wild type complex the flap elbows experience the largest movements among the 
different segments of the protease, as indicated by length of the PC1 displacement vectors 
(Figure 4). Hence, it is fair to say that the dynamic of the entire protease in the wild type 
form is mostly driven by flap elbows dynamics. The displacement vectors show that flap 
elbow from one of the protease chains moves in a clockwise manner pushing backward the 
80s loops which in turn push back the flap tip. At the same time the flap elbow from the 
other monomer moves in an anticlockwise manner so that both flap tips move together back 
and forth. These clockwise/anti-clockwise movements of the flap elbows involve some 
structural reorganization within each monomer. In particular, note that PC1 displacement 
vector from flap elbow point in different direction than PC1 vector from fulcrum suggesting 
that inter-residue interaction at the interface among these segments are affected due to flap 
elbow displacements.
On the other hand, in mutant variant bound to TL-3 (6X/TL-3) the clockwise/anti-clockwise 
movements of flap elbows is suppressed. Instead, flap elbow and fulcrum (as well as flap, 
cantilever and 80s loop from each monomer) move as a whole in an outward/inward manner, 
as indicated by the PC1 displacement vectors. As will be shown later, it seems that some of 
the point mutations on the protease reinforce the interactions at the interface between some 
of these segments preventing the clockwise/anticlockwise movement of flap elbows. As a 
consequence of the anti-correlated outward/inward movement of 6X protease monomers 
both flap tips get separated from each other. Curiously, when Br6 is bound to the flap site of 
6X/TL-3 complexes, flap elbows behave much like in the wild type form, i.e. they both 
move in a clockwise/anticlockwise correlated manner so that flap tips stay close together.
It is worth noting that the relative displacements recovered by PC1 are in an overall 
agreement with DCCM maps of the three complexes (Figure 3). Thus, the PC1 alone 
captures at least qualitatively the essential dynamics of the protease in the different 
complexes.
In view of the previous results we would like to know in more detail how mutations on the 
protease change its dynamical behaviour. And more importantly, how is Br6 able to restore 
back the dynamic of the mutant variant into the dynamic of the wild type form of the 
protease?
To answer these questions the charge density topological analysis on extreme projections 
along PC1 was performed next.
4.4 Charge Density Topological Analysis
Figures 5, 6 and 7 show the extreme projections along PC1 for the Wt/TL-3, 6X/TL-3 and 
6X/TL-3/Br6 complexes, respectively. Topological elements of the charge density were 
computed on selected zones of the extreme structures to reveal key interactions among 
structural segments of the protease.
Graphical representation of charge density topological elements (i.e. molecular graphs) 
allows capturing weak, hydrophobic interactions among different HIV-PR segments. These 
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hydrophobic interactions govern the protein dynamics and would be missed in a merely 
geometric analysis of the interactions.
Moreover, the charge density values at the interactions Bond Critical Points (BCPs) are 
considered as a measure of the strength of those interactions which allow us to measure 
whether the connections between any two segments of the HIV-PR become strengthened or 
otherwise weakened upon residue mutations or fragment binding.
Figure 8 shows the charge density networks between segments of the protease for the three 
complex systems studied here.
Expanded zones in the upper part of Figures 5, 6 and 7 show the interaction network 
involving both protease flap tips. In complexes Wt/TL-3 and 6X/TL-3/Br6 there are bond 
paths connecting backbone atoms of both flap tips to one another in both PC1 extreme 
projection structures which are in line with a correlated movement of flap tips.
While in complex 6X/TL-3, because of the anti-correlated motion of flaps tips, they are 
close enough for direct interaction in only one of the extreme projections. Therefore, bond 
paths connecting both flap tips backbone atoms are only observed in maximum PC1 extreme 
projection structure. Moreover, the charge density networks in Figure 8 show that 
interactions between both flap tips are stronger in the first complexes than in last one which 
is also in line with the fact that flap tips stay close together in the first case but open apart in 
the last one.
More clues about origin of different behaviour of flap tips can be found by inspecting flap 
elbow interactions. Expanded zones to the right of Figures 5, 6 and 7 show the main 
interactions of flap elbow with neighbouring segments in monomer A of protease 
complexes.
As indicated by arrows in Figure 5 (right panel) for the wild type complex, on going from 
the minimum PC1 projection (purple) to the maximum one (cyan) the flap elbow moves in 
anti-clockwise manner bringing forward the 80s loop which in turn causes the forward shift 
of flap tip. The displacement of flap elbow causes the rupture of hydrogen bonds (H-bonds) 
that Asn37 and Met36 from this segment form with fulcrum residues Gln18 and Lys20, 
respectively and also cause the rupture of interaction between Asn37 with cantilever residue 
Tyr59. Thus, transition from minimum to maximum PC1 projection structures involves the 
breaking of (at least) three H-bonds that hold flap elbow in place. At the same time, in flap 
elbow from the other protease monomer the inverse changes are occurring so that enthalpy 
penalty of breaking H-bonds in one monomer might be compensated by their formation in 
the other.
On the other hand, in the mutant variant 6X/TL-3 the flap elbow moves outward on going 
from minimum to maximum PC1 projection, as indicated by the arrows in Figure 6, right 
expanded zone.
Note in this figure that cantilever residue Pro63, which is one of the mutated residues in 6X 
variant, is connected through bond paths to residue Gly16 from fulcrum tip, in both extreme 
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projections. While in the wild type complex residue Leu63 does not form any strong 
interaction with fulcrum tip as depicted in Figure 5, right panel.
In complex 6X/TL-3, the O@P63••••H@G16 interaction holds the fulcrum tip close to flap 
elbow in such a way that they cannot be detached from each other. Note that, unlike the wild 
type complex, the interactions of elbow with fulcrum residues Gln18 and Lys20 are still 
formed upon transition from one extreme structure to the other. Therefore, as flap elbow 
moves in outward manner, it drags with it the fulcrum tip and cantilever so that the three 
segments move together as a whole.
As indicated by the arrows in Figure 6 (right expanded zone) this mass movement involves a 
downward shift of cantilever and outward/downward movement of the contiguous flap 
segment, which explains at least in part the PC1 displacement vectors of complex 6X/TL-3 
in Figure 4.
Moreover, another point mutation V66I also seems to be involved in the outward movement 
of flaps in mutant complex 6X/TL-3. In this complex, residue Ile77 at 80s loop extends 
down the flap elbow and forms interactions with side chain of Met36 which in turn is 
connected through bond paths to Lys20 at fulcrum (Figure 6, right panel). Thus, Ile77 is 
connected via Met36 with fulcrum resides and so, the motion of 80s loop is correlated with 
movement of fulcrum, elbow and cantilever, as indicated by the orange arrows in Figure 6, 
right panel. In turn, 80s loops drags down with it flap base residues since both segments are 
forming a β-sheet motif and so they are firmly associated to each other. On the other hand, 
in wild type complex the shortest side chain of Val77 cannot reach Met36 side chain and so 
its motion is not correlated with that of fulcrum segment (note in Figure 5 that there isn’t 
any topological element connecting Val77 with Met36 in the wild type complex).
Thus, these point mutations (i.e L63P and V77I) seem to increase the strength of the 
interactions among different segments of the protease thus preventing the clockwise/anti-
clockwise movement of flap elbows necessary for a correlated motion of both flaps tips. As 
evidenced from the charge density networks of Figure 8, the edges connecting most of the 
segments of the protease are quite wider in complex 6X/TL-3 than in wild-type complex, 
which further supports the previous statement.
Regarding ternary complex 6X/TL-3/Br6 its protein backbone shift is quite more subtle than 
in previous systems, on going from one extreme projection to the other (see Figure 7, right 
expanded zone). The most dramatic shift occurs in the flap elbow which, as in wild type 
complex, experiences an anti-clockwise movement on going from minimum to maximum 
PC1 projection structure. It is worth noting the rupture of the strong salt bridge between 
Arg57 at flap base and Glu35 at elbow that is otherwise formed in PC1 extreme projection 
structures of complexes 6X/TL-3 and Wt/TL-3. By inspecting Figure 7 it is evident that Br6 
directly perturbs the salt bridge as evidenced by the bond paths connecting the Br6 bulky 
bromine atom with R57 side chain atoms. This strong interaction (i.e. R57 to E36) holds 
firmly the flap elbow to the flap base, hence it is expected that after its disruption flap elbow 
could move more freely and independently from other segments of the protease thus 
mimicking the wild type elbow motion. In fact note in the charge density network of ternary 
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complex 6X/TL-3/Br6 that interactions between flap and elbow becomes much weaker after 
Br6 has bound to 6X/TL-3 (Figure 8). Also interactions of elbow with fulcrum and 80s loop 
residues become weaker after fragment bound to flap site. Thus, the result of salt bridge 
disruption is the release of flap elbow in the resistant form of the protease.
5 Conclusions
In this work we have performed long MD simulations of wild type and 6X mutant form of 
HIV-PR bound to potent inhibitor TL-3. The simulations show that on going from Wt/TL-3 
to 6X/TL-3 the equilibrium shifts from closed to semi-open conformation of the flaps, in 
agreement with previous experimental and theoretical evidence. Then we placed small 
fragments Br6 and Br27 to the flap and exo sites of 6X/TL-3 and performed MD simulations 
of the ternary complexes 6X/TL-3/Br6 and 6X/TL-3/Br27. Surprisingly one of the 
fragments, Br6, was able to restore back the enzyme to closed conformation of the flaps.
PCA and QTAIM charge density analysis provided some clues about the mechanism of flap 
opening and closing in 6X/TL-3 and 6X/TL-3/Br6, respectively. Mutations L63P and V77I 
seem to increase the strength of the interactions among different segments of 6X/TL-3 thus 
preventing the clockwise/anti-clockwise movement of flap elbows required for keeping both 
flap tips closed together in a correlated motion. On the other hand when Br6 is placed at flap 
site of 6X/TL-3, it perturbs the R57•••E35 salt bridge that hold firmly the flap elbow to flap 
base. Thus, the result of salt bridge disruption is the release of flap elbow and restoration of 
clockwise/anti-clockwise motion in the resistant form of the protease. In other words, small 
fragment Br6 once bound to flap site of 6X protease variant is able to turn the dynamics of 
mutant protease variant into the dynamics of the wild type form. It still remains to be proven 
if these results are reproducible in vitro. If that were the case, small fragments could be 
added to AIDS patient’s treatment plans to overcome resistance to HIV-PR inhibitors.
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Backbone distance Cα@I50⋯Cα@I50’ between both flap tips along MD trajectories.
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Distance between center of mass (CM) of small fragment Br6 and CM of flap site along MD 
trajectories of complex 6X/TL-3/Br6. Flap site is defined by residues L55, R57, I46 and P44 
that conform the walls of Br6 binding pocket in 6X mutant. A snapshot of Br6 binding 
pocket in 6X protease variant is shown at the bottom of figure.
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Correlations between protease residues in complexes Wt/TL-3, 6X/TL-3 and 6X/TL-3/Br6. 
On the right, the two-dimensional Dynamic Cross Correlation Maps (DCCMs) are depicted. 
On the left, the positive correlations between residues were drawn as red lines on the protein 
structure. Note that while flaps are mostly negatively correlated (circled zone in the 
DCCMs) there is a positive correlation region between flaps tips in complexes Wt/TL-3 and 
6X/TL-3/Br6 (indicated with an arrow in the DCCMs and by the red lines connecting both 
flaps on the 3D protein structure)
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Vector field representation of PC1 obtained from the MD trajectories.
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Extreme projections along PC1 for the Wt/TL-3 complex (maximum and minimum PC1 
projections are depicted in cyan and purple, respectively). Topological elements of the 
charge density are shown for selected zones on the extreme structures. Bond paths 
connecting the nuclei are depicted in cyan and purple for maximum and minimum 
projections, respectively and the small red circles on them show the bond critical points 
(BCPs).
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Extreme projections along PC1 for the mutant 6X/TL-3 complex (maximum and minimum 
PC1 projections are depicted in cyan and purple, respectively). Topological elements of the 
charge density are shown for selected zones on the extreme structures. Bond paths 
connecting the nuclei are depicted in cyan and purple for maximum and minimum 
projections, respectively and the small red circles on them show the bond critical points 
(BCPs).
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Extreme projections along PC1 for the mutant 6X/TL-3/Br6 complex (maximum and 
minimum PC1 projections are depicted in cyan and purple, respectively). Topological 
elements of the charge density are shown for selected zones on the extreme structures. Bond 
paths connecting the nuclei are depicted in cyan and purple for maximum and minimum 
projections, respectively and the small red circles on them show the bond critical points 
(BCPs).
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Charge density networks for the three complex systems studied here. Each node of the 
network represents a community of residues from a particular segment of the protease and 
the width of edges connecting the nodes are proportional to the sum of charge density values 
at the inter-segment bond critical points, averaged over the two PC1 extreme projection 
structures (Σρb). The Σρb values (in atomic units) are depicted on the corresponding edges.
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